Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics
June 17, 2021 08:05 ET
|
Revive Therapeutics Ltd.
TORONTO, June 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive To Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
June 14, 2021 17:00 ET
|
Revive Therapeutics Ltd.
TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India
June 08, 2021 08:38 ET
|
Revive Therapeutics Ltd.
TORONTO, June 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip
May 17, 2021 09:24 ET
|
Revive Therapeutics Ltd.
TORONTO, May 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19
May 03, 2021 09:15 ET
|
Revive Therapeutics Ltd.
TORONTO, May 03, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury
April 27, 2021 09:17 ET
|
Revive Therapeutics Ltd.
TORONTO, April 27, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional Patent Application
April 22, 2021 08:00 ET
|
Revive Therapeutics Ltd.
TORONTO, April 22, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Reschedules Annual and Special Meeting and Provides Dial-In Information
April 15, 2021 18:00 ET
|
Revive Therapeutics Ltd.
TORONTO, April 15, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Adjourns Annual and Special Meeting
April 12, 2021 12:54 ET
|
Revive Therapeutics Ltd.
TORONTO, April 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics...
Revive Provides Dial-In Information for Annual and Special Meeting
April 08, 2021 18:00 ET
|
Revive Therapeutics Ltd.
TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...